logo-loader

AstraZeneca asthma treatment does well in final trial

Published: 10:31 05 Sep 2016 EDT

picture of cigarette smoke
Benralizumab can offer a meaningful treatment option said Astra

A new AstraZeneca (LON:AZN) treatment generated significant improvements for severe asthma sufferers in its final trial, the pharma giant revealed today.

Results showed that adding benralizumab to standard-of-care medicine reduced exacerbations by up to 51%, improved lung function after four weeks and reduced wheeze, cough, chest tightness and shortness of breath

Sean Bohen, chief medical officer, said: “The SIROCCO and CALIMA Phase III trials have shown that benralizumab can offer a meaningful treatment option for patients."

Up to 10% of asthma cases are severe, which 40% of these  uncontrolled on current standard of care medicine. Severe, uncontrolled asthma has an eight times higher risk of mortality than severe asthma.

Shares eased 37p to 4,904p in London.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

44 minutes ago